211374-82-2

Basic information

• Product Name: 4-Amino-3-methoxybenzamide
• Synonyms: 4-Amino-3-methoxybenzamide
• CAS NO: 211374-82-2
• Molecular Formula: C₈H₁₀N₂O₂
• Molecular Weight: 166.1772
• Mol File: 211374-82-2.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-Amino-3-methoxybenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Amino-3-methoxybenzamide(211374-82-2)
• EPA Substance Registry System: 4-Amino-3-methoxybenzamide(211374-82-2)

Safety Data

• Hazardous Substances Data: 211374-82-2(Hazardous Substances Data)

Upstream product

• 41608-64-4 methyl 3-methoxy-4-aminobenzoate 
• 2486-69-3 3-methoxy-4-aminobenzoic acid 
• 67579-92-4 3-methoxy-4-nitrobenzoic acid chloride 
• 5081-36-7 3-methoxy-4-nitrobenzoic acid 
• 92241-87-7 3-methoxy-4-nitrobenzamide 
• 403-21-4 3-fluoro-4-nitrobenzoic acid 
• 185629-31-6 methyl 3-fluoro-4-nitrobenzoate 

Downstream Products

• 1377582-20-1 3-methoxy-4-thioureido-benzamide 
• 1022968-27-9 C₁₂H₁₀Cl₂N₄O₂ 

Relevant articles and documents

METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to tricycle I and its therapeutic and prophylactic uses, wherein the variables C1, C2, Z1, Z2, Q, J, R1, and R3 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to bisthiazole I and its therapeutic and prophylactic uses, wherein the variables A, R5, R6, and R7 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.